AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2005315
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to IgE sensitizing agents
Trial: 6650801
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg kg‐1 i.v.
Trial: 6650801
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg kg‐1 i.v.
Trial: 31250427
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (medication reconciliation)
Trial: 30941435
Drug: Beak trimming
RxNorm normalized name: phentermine hydrochloride Oral Capsule [Oby-Trim]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beak trimming twice (7 and 70 days old)
Trial: 22055112
Drug: FOLF-CB (cetuximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLF-CB (cetuximab 400 mg/m2 day 1 cycle 1; subsequent doses 250 mg/m2 weekly, along with bevacizumab, leucovorin, and 5-FU)
Trial: 22055112
Drug: mFOLFOX6-B (bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6-B (bevacizumab 5 mg/kg, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and 5-FU 400 mg/m2 then 1200 mg/m2/day for 48 hours)
Trial: 19182972
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser (30 Hz, 60 mJ for 10 sec, without water/air spray)
Trial: 16055645
Drug: Training in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training in Oriental medicine
Trial: 16055645
Drug: Length of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Length of training in Oriental medicine
Trial: 2660550
Drug: Sucralfate suspension
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate suspension 1 g/10 ml four times per day
Trial: 2660550
Drug: Cigarette smoking
RxNorm normalized name: Cigarette smoking tobacco
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette smoking (regardless of treatment group)
Trial: 20724681
Drug: Active water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active water treatment units
Trial: 20724681
Drug: Sham water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham water treatment units
Trial: 15561950
Drug: GAD antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD antibody positive patients
Trial: 15561950
Drug: GAD antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD antibody negative patients
Trial: 2917399
Drug: Opti-Free chemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opti-Free chemical disinfectant under normal daily use (Group A)
Trial: 2917399
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily use regimen (Group B)
Trial: 21747241
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg monotherapy
Trial: 30273819
Drug: Leucine-enriched amino
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-enriched amino acid supplement
Trial: 30273819
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no leucine-enriched amino acid supplement)
Trial: 28545580
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) after 5 therapy-preparing sessions
Trial: 26325427
Drug: Intra-oral autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-oral autologous bone graft
Trial: 26325427
Drug: Implant stability
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant stability quotient (ISQ)
Trial: 19624628
Drug: Supraclavicular block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraclavicular block with 2% lidocaine 25‐30 ml and adrenaline 5 microg.ml(‐1)
Trial: 19624628
Drug: Infraclavicular block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infraclavicular block with 2% lidocaine 25‐30 ml and adrenaline 5 microg.ml(‐1)
Trial: 11706909
Drug: Acetaminophen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (600 mg) with codeine (60 mg) and caffeine (15 mg) (Tylenol No. 3)
Trial: 18334689
Drug: Monthly personal
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly personal contact
Trial: 17142406
Drug: Hip core
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip core decompression followed by physical therapy
Trial: 14563339
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with abciximab (0.25mg/kg bolus and 0.125 microg/kg/min for 12h) and half‐dose reteplase (two boluses of 5U 30 min apart) with reduced‐dose heparin (60 Ukg(‐1) bolus, maximum 5000 U, followed by an infusion of 7 Ukg(‐1)h(‐1))
Trial: 14563339
Drug: Reteplase alone
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reteplase alone (10 U bolus twice, 30 min apart) with standard‐dose heparin (5000 U bolus followed by an infusion of 1000 Uh(‐1) for patients > or =80 kg and 800 Uh(‐1) for those <80 kg)
Trial: 11056590
Drug: HIV‐1 Immunogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐1 Immunogen administered intramuscularly every 12 weeks
Trial: 4029017
Drug: Temocillin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin 0.5 g intravenous
Trial: 4029017
Drug: Temocillin 1
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin 1 g intravenous
Trial: 4029017
Drug: Temocillin 2
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin 2 g intravenous
Trial: 4029017
Drug: Temocillin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin 0.5 g intramuscular
Trial: 4029017
Drug: Dose-reduction factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-reduction factors for temocillin
Trial: 29415606
Drug: Ibuprofen medicated
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen medicated plaster
Trial: 17378911
Drug: Ghrelin concentration
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin concentration greater than 3,200 pg/mL (fourth quartile)
Trial: 9788404
Drug: Combined chemoradiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemoradiotherapy (5-fluorouracil, mitomycin C, and radiation therapy)
Trial: 2650015
Drug: Acyclovir in
RxNorm normalized name: acyclovir Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir in propylenglycol (40% cream)
Trial: 31617562
Drug: Clinical geriatric
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical geriatric assessments and collaborative medication reviews by geriatrician and family physician (FP)
Trial: 28118537
Drug: AMG 811
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 811 (180 mg)
Trial: 17455207
Drug: Weekend 5-ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekend 5-ASA enema (1 g twice a week) plus oral 5-ASA (3 g/day)
Trial: 17455207
Drug: Oral 5-ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-ASA only (3 g/day)
Trial: 14522627
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 4% gel (BID)
Trial: 14522627
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel (QD)
Trial: 10968648
Drug: Acupuncture in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture in combination with tooth extraction
Trial: 10968648
Drug: Acupuncture used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture used in combination with local anesthesia
Trial: 9202556
Drug: SR alfuzosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR alfuzosin 5 mg twice daily
Trial: 1283570
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 240 mg/day
Trial: 28415881
Drug: Step by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step by Step treatment protocol (intervention)
Trial: 27367159
Drug: Spironolactone 20
RxNorm normalized name: spironolactone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 20 mg once daily (up to 40 mg once daily for 4 weeks if required)
Trial: 25069531
Drug: 10‐mg metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg metoclopramide thrice daily for 15 days
Trial: 25069531
Drug: 10‐mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg placebo thrice daily for 15 days
Trial: 19272808
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (splint, heat, and exercise)
Trial: 17289855
Drug: Bilateral eccentric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral eccentric overload strength training using the Bromsman device twice a week
Trial: 17289855
Drug: Unilateral eccentric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unilateral eccentric body load training using a decline board twice a week
Trial: 15336780
Drug: Post-vaccine PBL
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-vaccine PBL
Trial: 11148437
Drug: Lansoprazole-based triple
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole-based triple therapy for 7 days
Trial: 8929937
Drug: Willingness for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness for treatment
Trial: 8929937
Drug: Treatment tenure
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment tenure
Trial: 2780404
Drug: No exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exercise treatment (Control Group)
Trial: 329423
Drug: Delta-9-tetrahydrocannabinol (0.022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta-9-tetrahydrocannabinol (0.022 mg/kg and 0.044 mg/kg)
Trial: 31818699
Drug: Apomorphine sublingual
RxNorm normalized name: apomorphine Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine sublingual film (10-35 mg)
Trial: 31818699
Drug: Apomorphine sublingual
RxNorm normalized name: apomorphine Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine sublingual film
Trial: 26472122
Drug: Low-dose X-ray
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose X-ray system with advanced real-time image processing
Trial: 16507327
Drug: Aprinocarsen (2mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprinocarsen (2mg/kg/day continuous iv infusion for the first 14 days of each cycle), combined with gemcitabine (1,250 mg/m² on days 1 and 8) and carboplatin (AUC 5 on day 1 every 21 days).
Trial: 14747106
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (suturing)
Trial: 9164203
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of standard adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy
Trial: 9164203
Drug: One cycle
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of perioperative CMF therapy
Trial: 8394880
Drug: ImuVert and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ImuVert and radiation therapy (RT)
Trial: 29864779
Drug: Vorapaxar (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar (10 mg initial dose, potentially an additional 10 mg based on aggregometry)
Trial: 22049096
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg once daily for six months
Trial: 22049096
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice daily for six months
Trial: 16551284
Drug: Hemodialysis dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis dose defined by K/DOQI guidelines (spKt/V of 1.2)
Trial: 16551284
Drug: Hemodialysis dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis dose defined by European guidelines (spKt/V of 1.4)
Trial: 16551284
Drug: Normalization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normalization of dialysis dose for low molecular weight water-soluble solutes (urea)
Trial: 16551284
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of spKt/V or eKt/V for routine monitoring of hemodialysis dose
Trial: 16551284
Drug: Dialysis dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis dose dependent on gender
Trial: 16551284
Drug: Dialysis dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis dose for middle molecules in clinical practice
Trial: 16551284
Drug: Dialysis dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis dose for more frequent hemodialysis treatment strategies
Trial: 15451901
Drug: Insulin glulisine/NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glulisine/NPH (n = 435)
Trial: 15451901
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (RHI)/NPH (n = 441)
Trial: 10633218
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose infusion of insulin (HDT)
Trial: 10633218
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose infusion of insulin (LDT)
Trial: 8659772
Drug: Sustained-release ibuprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release ibuprofen, 2 x 800 mg (n = 57)
Trial: 2058222
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (400 mg)
Trial: 2058222
Drug: Theophylline administered
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline administered via endoscope into the colon transversum
Trial: 6097457
Drug: ACTH 4-9
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-9 analogue (40 mg)
Trial: 31246579
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (2000-2500 g)
Trial: 31246579
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (2500-3000 g)
Trial: 31246579
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (3000-3500 g)
Trial: 31246579
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (3500-4000 g)
Trial: 28810909
Drug: Eosinophil-guided corticosteroid-sparing
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosinophil-guided corticosteroid-sparing therapy (prednisolone not administered if eosinophil level < 0.3 × 10^9 cells/L)
Trial: 28810909
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (5-day course of high-dose systemic corticosteroids)
Trial: 28810909
Drug: Eosinophil-guided corticosteroid-sparing
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosinophil-guided corticosteroid-sparing therapy
Trial: 22821925
Drug: US-guided pararadicular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided pararadicular injections
Trial: 21082298
Drug: Oral caffeine
RxNorm normalized name: caffeine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral caffeine 200 mg
Trial: 21082298
Drug: Oral caffeine
RxNorm normalized name: caffeine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral caffeine 400 mg
Trial: 19118324
Drug: Haloperidol (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5-15 mg/day)
Trial: 11242608
Drug: Inhaled flunisolide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled flunisolide, 500 mg twice a day for 2 years
Trial: 11242608
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (asthma patients not requiring glucocorticoid treatment)
Trial: 8452386
Drug: l-leucovorin 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-leucovorin 250 mg/m2 weekly
Trial: 8452386
Drug: l-leucovorin 100
RxNorm normalized name: leucovorin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-leucovorin 100 mg/m2 for 5 consecutive days
Trial: 8452386
Drug: l-leucovorin 10
RxNorm normalized name: leucovorin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-leucovorin 10 mg/m2 for 5 consecutive days
Trial: 3512663
Drug: Slo-bid capsules
RxNorm normalized name: Slo-bid
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slo-bid capsules
Trial: 24648266
Drug: ALL-related treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALL-related treatments
Trial: 20979455
Drug: Intranasal Norwalk
RxNorm normalized name: Norwalk virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Norwalk VLP vaccine (100-μg dosage)
Trial: 20979455
Drug: Intranasal Norwalk
RxNorm normalized name: Norwalk virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Norwalk VLP vaccine (50-μg dosage)
Trial: 20979455
Drug: Intranasal Norwalk
RxNorm normalized name: Norwalk virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Norwalk VLP vaccine (50-μg and 100-μg dosages)
Trial: 11951579
Drug: 5% ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% ibuprofen cream (Dolgit cream), applied in a 10-cm strip t.i.d. for 7 days, each strip containing approximately 200 mg ibuprofen.
Trial: 11951579
Drug: Placebo cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream, applied in the same manner as the ibuprofen cream.
Trial: 8090332
Drug: Oral 1
RxNorm normalized name: SYRINGE,ORAL 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Trial: 8090332
Drug: Intravenous 1
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Trial: 8090332
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Trial: 8090332
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intraperitoneal 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Trial: 8090332
Drug: Oral, intraperitoneal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Trial: 30912719
Drug: CT examinations
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT examinations with intravenous contrast agent (n = 4263)
Trial: 30912719
Drug: CT examinations
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT examinations without intravenous contrast agent (n = 16,111)
Trial: 25933487
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with 900 mg of eicosapentaenoic acid plus 680 mg of docosahexaenoic acid for 4 weeks
Trial: 19748293
Drug: IANB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IANB plus buccal infiltration (BI)
Trial: 19748293
Drug: IANB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IANB plus periodontal ligament (PDL) injection
Trial: 10763910
Drug: Phentermine hydrochloride
RxNorm normalized name: Phentermine Hydrochloride
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phentermine hydrochloride therapy plus a low energy diet (5040 kJ/d)
Trial: 8973780
Drug: Lacidipine-based treatment
RxNorm normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine-based treatment
Trial: 8973780
Drug: Beta-blocker (atenolol)-based
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (atenolol)-based treatment